Aviceda Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
33
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$207M
- Investors
-
13
Aviceda Therapeutics General Information
Description
Operator of a biotechnology company intended to develop breakthrough glycol-therapeutics for patients. The company combines biology with a cell-based screening platform and proprietary nanoparticle technology to modulate the innate immune response and lead to ophthalmic-optimized nanoparticles, enabling medical researchers to address chronic non-resolving inflammation in patients.
Contact Information
Website
www.avicedarx.comCorporate Office
- One Broadway
- 14th Floor
- Cambridge, MA 02142
- United States
Corporate Office
- One Broadway
- 14th Floor
- Cambridge, MA 02142
- United States
Aviceda Therapeutics Timeline
Aviceda Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series C) | 07-Jan-2025 | $207M | Completed | Clinical Trials - Phase 2 | ||
| 5. Later Stage VC (Series B) | 31-May-2024 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series AA) | 19-May-2023 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series A) | 24-Oct-2022 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A) | 16-Sep-2020 | $4.25M | $4.25M | Completed | Clinical Trials - Phase 2 | |
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 |
Aviceda Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-2 | ||||||||
| Series C-1 | ||||||||
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series AA | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 2,538,659 | $0.000010 | $1.84 | $1.84 | 1x | $1.84 | 4.22% | |
| Series A-1 | 1,115,731 | $0.000010 | $4.42 | $4.42 | 1x | $4.42 | 1.85% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Aviceda Therapeutics Comparisons
Industry
Financing
Details
Aviceda Therapeutics Competitors (80)
One of Aviceda Therapeutics’s 80 competitors is Foghorn Therapeutics, a Formerly VC-backed company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Foghorn Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Certa Therapeutics | Venture Capital-Backed | Melbourne, Australia | ||||
| Kymera Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Shinobi Therapeutics | Venture Capital-Backed | South San Francisco, CA | ||||
| Arvinas | Formerly VC-backed | New Haven, CT |
Aviceda Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aviceda Therapeutics Patents
Aviceda Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024252577-A1 | Polysialic acid-polymer conjugate and nanoparticle | Pending | 14-Apr-2023 | ||
| EP-4694933-A1 | Polysialic acid-polymer conjugate and nanoparticle | Pending | 14-Apr-2023 | ||
| WO-2024215999-A1 | Polysialic acid-polymer conjugate and nanoparticle | Inactive | 14-Apr-2023 | ||
| AU-2022426713-A1 | Glycomimetic ligands | Pending | 31-Dec-2021 | ||
| EP-4457235-A1 | Glycomimetic ligands | Active | 31-Dec-2021 | A61K47/6937 |
Aviceda Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aviceda Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aberdeen Investments (Scotland) | Asset Manager | Minority | ||
| Blue Owl Capital | Asset Manager | Minority | ||
| Digitalis Ventures | Venture Capital | Minority | ||
| Enavate Sciences | Venture Capital | Minority | ||
| Jeito | Growth/Expansion | Minority |
Aviceda Therapeutics FAQs
-
When was Aviceda Therapeutics founded?
Aviceda Therapeutics was founded in 2018.
-
Where is Aviceda Therapeutics headquartered?
Aviceda Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Aviceda Therapeutics?
Aviceda Therapeutics has 33 total employees.
-
What industry is Aviceda Therapeutics in?
Aviceda Therapeutics’s primary industry is Biotechnology.
-
Is Aviceda Therapeutics a private or public company?
Aviceda Therapeutics is a Private company.
-
What is the current valuation of Aviceda Therapeutics?
The current valuation of Aviceda Therapeutics is .
-
What is Aviceda Therapeutics’s current revenue?
The current revenue for Aviceda Therapeutics is .
-
How much funding has Aviceda Therapeutics raised over time?
Aviceda Therapeutics has raised $276M.
-
Who are Aviceda Therapeutics’s investors?
Aberdeen Investments (Scotland), Blue Owl Capital, Digitalis Ventures, Enavate Sciences, and Jeito are 5 of 13 investors who have invested in Aviceda Therapeutics.
-
Who are Aviceda Therapeutics’s competitors?
Foghorn Therapeutics, Certa Therapeutics, Kymera Therapeutics, Shinobi Therapeutics, and Arvinas are some of the 80 competitors of Aviceda Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
